How does molecular complexity translate into formulation and manufacturability challenges?

What can bispecific antibodies teach us about identifying formulation risks from molecular liabilities?

How can predictive and data-driven approaches support smarter formulation and CMC decisions?

Where can computational and experimental strategies be integrated to accelerate development of next-generation biologics?

What capabilities will CMC organizations need as antibody therapeutics become increasingly complex?